Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. by Shovik Bandyopadhyay, Junjie Li, Elie Traer, Jeffrey W Tyner, Amy Zhou, Stephen T Oh, Ji-Xin Cheng

“…Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. …”
Get full text

A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells by Sara Ceccacci, Lorenzo Corsi, Lucio Spinelli, Clarissa Caroli, Matilde Marani, Lisa Anceschi, Matteo Mozzicafreddo, Federica Pellati, Maria Chiara Monti

Subjects: Get full text

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature by Narender Kumar, Jasmina Ahluwalia, Pankaj Malhotra, Man Updesh Singh Sachdeva

Subjects: Get full text

SDF-1α Reduces Human Natural Killer Cell Cytotoxicity against Chronic Myelogenous Leukemia K562 Cells by Alireza Mardomi, Hadi Hossein-Nataj, Narjes Jafari, Nabiallah Mohammadi, Saeid Abediankenari

Get full text

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia by Hu Lei, Han-Zhang Xu, Hui-Zhuang Shan, Meng Liu, Ying Lu, Zhi-Xiao Fang, Jin Jin, Bo Jing, Xin-Hua Xiao, Shen-Meng Gao, Feng-Hou Gao, Li Xia, Li Yang, Li-Gen Liu, Wei-Wei Wang, Chuan-Xu Liu, Yin Tong, Yun-Zhao Wu, Jun-Ke Zheng, Guo-Qiang Chen, Li Zhou, Ying-Li Wu

“…Resistance to tyrosine kinase inhibitors (TKI) is a limitation to their use in treating chronic myelogenous leukemia (CML). Here, the authors show that targeting the ubiquitin peptidase USP47 overcomes TKI resistance and eliminates leukaemia stem/progenitor cells in primary and xenograft CML murine models.…”
Get full text

Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. by Soumyajit Banerjee Mustafi, Prabir K Chakraborty, Sanghamitra Raha

“…BACKGROUND: Resveratrol is known to downregulate the high endogenous level of Heat shock protein 70 (Hsp70) in Chronic Myelogenous Leukemia (CML) K562 cells and induce apoptosis. …”
Get full text

Chronic myelogenous leukemia fase akselerasi pada anak dengan asidosis metabolik dan gizi kurang : Suatu laporan kasus by Perpustakaan UGM, i-lib

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? by Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati

Subjects: “…chronic myelogenous leukemia…”
Get full text

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? by Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati

Subjects: “…Chronic myelogenous leukemia…”
Get full text

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters by Mervat M. Omran, MD, Samia A. Shouman, PhD, Raafat Abdelfattah, MD, Heba S. Moussa, MD, Nadia A. Thabet, Msc, Marwa S. Hamza, PhD

“…Objective: The aim of the present work is to study the association between the plasma concentrations of IM and plasma 25-hydroxyvitamin (25[OH]) D3 with transporter genotypes in patients with chronic myelogenous leukemia. Methods: A total of 77 adult patients with chronic myelogenous leukemia treated with IM participated in this study. …”
Get full text

Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model by Ya-Kai Fu, Yun Tan, Bo Wu, Yu-Ting Dai, Xiao-Guang Xu, Meng-Meng Pan, Zhi-Wei Chen, Niu Qiao, Jing Wu, Lu Jiang, Jing Lu, Bing Chen, Avigail Rein, Shai Izraeli, Xiao-Jian Sun, Jin-Yan Huang, Qiu-Hua Huang, Zhu Chen, Sai-Juan Chen

Get full text

Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic Myelogenous Leukemia Patients by Soheila Manaflouyan Khajehmarjany, Seyed Ali Rahmani, Seyed Hadi Chavoshi, Ali Esfahani, Ali Akbar Movassaghpour Akbari

Get full text

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature by Gilbert Bader MD, Bernard Dreiling MD

Get full text

Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study by Manar Mohamd Mohamad Ismail, Moneer M. Manar

“…OBJECTIVE: Chronic myelogenous leukemia (CML) is a clonal stem cell disease and is consistently associated with the BCR-ABL fusion gene. …”
Get full text

Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications by Dongfang Ouyang, Ningxin Ye, Kun Yang, Yiyang Wang, Lina Hu, Shuen Chao, Mehmet Toner, Yonghua Li

Subjects: Get full text

The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients by Serap Yalçın, Pelin Mutlu, Türker Çetin, Meral Sarper, Gökhan Özgür, Ferit Avcu

Subjects: Get full text

A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report by Alexander B Aria, Leon Chen, Auris O Huen

“…Bosutinib is a BCR-ABL tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia. We report a case of bosutinib-induced interstitial granulomatous drug reaction in a 50-year-old Caucasian female with chronic myelogenous leukemia. …”
Get full text

Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia by Eunjung Kim, Eo-Jin Hwang, Junghye Lee, Dae-Young Kim, Jae-Young Kim, Dong-Wook Kim

Subjects: “…Chronic myelogenous leukemia…”
Get full text

AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects by Meher Bolisetti Gayatri, Rama Krishna Kancha, Abhayananda Behera, Dorababu Patchva, Nagaraj Velugonda, Sadasivudu Gundeti, Aramati Bindu Madhava Reddy

Get full text

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. by Silvia Catellani, Ivana Pierri, Marco Gobbi, Alessandro Poggi, Maria Raffaella Zocchi

“…Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. …”
Get full text